



## **Shionogi and FunPep enter into a licensing agreement on the functional peptide which accelerates wound-healing, SR-0379**

---

Osaka and Tokyo, Japan, October 29, 2015 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) and FunPep Co., Ltd., a biotechnology venture company based on technology of Osaka University (Head Office: Tokyo, Japan; Representative Director, President and CEO: Akimitsu Hirai, LL.M.; hereafter “FunPep”) today announced that the companies have entered into a licensing agreement to accelerate development of the functional peptide SR-0379, which accelerates wound healing. Under the terms of the agreement, Shionogi acquired exclusive global rights to SR-0379 and will be responsible for all future research, development, manufacturing, and commercialization.

SR-0379 is a synthetic anti-microbial peptide consisting of 20 amino acids, originally discovered from a basic research in Osaka University, and whole intellectual property rights for the peptide had been transferred to FunPep. In preclinical animal studies, SR-0379 showed acceleration for granulation activity. SR-0379 is expected to be a new therapeutic option for the treatment of intractable cutaneous ulcers such as decubitus ulcers, and to contribute to increment in social needs from home medical care.

Shionogi is dedicated to addressing the increasing medial need in both the hospital and nursing home settings by developing and launching SR-0379 as soon as possible. Through this and many other programs, Shionogi remains dedicated to developing innovative medicines from unique drug seeds discovered in academia to provide patients globally with important new medicines as a drug discovery-based pharmaceutical company.

### **About decubitus ulcers**

Decubitus ulcers are skin wounds that result from prolonged pressure on the skin that is in contact with a bed or wheelchair in bedridden or paralyzed patients whose movement is limited. They can lead to severe pain, and are prone to infection, and are associated with increased rates of mortality.

### **About FunPep**

Established: October 11, 2013

Representative Director, President and CEO: Akimitsu Hirai, LL.M.

Head office: 9-11-212, 1-chome Sendagaya, Shibuya-ku, Tokyo, 151-0051 Japan

FunPep Co., Ltd. is a biotechnology venture company focused on the development of functional peptides derived from the platform technology from the Graduate School of Medicine, Osaka University. FunPep is planning to pursue applications of its technology across a wide range of fields, including cosmetics, medical devices, regenerative medicine and ethical drugs.

**Forward-looking statements**

*This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.*

**For further information, contact:**

Corporate Communications Department

Shionogi & Co., Ltd.

Tel: +81-6-6209-7885

Fax: +81-6-6229-9596

Tokyo Office

FunPep Co., Ltd.

Tel: +81-3-6721-1237

Fax: +81-3-6721-1238